Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.

ABSTRACT:

Objective

To evaluate the performance of Bladder Epicheck® (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette-Guérin (BCG) failure during the first year after induction treatment.

Patients and methods

Prospective study including 65 patients with non-muscle-invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment.

Results

During follow-up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high-grade

SUBMITTER: Roldan FL 

PROVIDER: S-EPMC12415308 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature